Eyenovia, Inc. Announces Plans for a New Public Offering
Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, has revealed its intention to offer and sell shares of its common stock (or pre-funded warrants in place of common stock) through a best efforts offering. All securities involved in this offering will be provided by Eyenovia. Please note that the offering is contingent upon market conditions, and there is no guarantee regarding the timing, completion, or specific terms of the offering.
Intended Use of Proceeds
The Company plans to utilize the net proceeds from this offering to support commercialization efforts for Mydcombi and clobetasol propionate, to complete the CHAPERONE pediatric myopia clinical study, and for general working capital and corporate needs, which may include paying down a portion of existing debt.
Placement Agent Information
Dawson James Securities, Inc. has been appointed as the sole placement agent for this offering.
Regulatory Filings Overview
This offering is being conducted under a shelf registration statement on Form S-3, which includes a base prospectus, that has been filed with the U.S. Securities and Exchange Commission (the “SEC”). The offering will proceed solely through a prospectus supplement and the accompanying prospectus. A preliminary prospectus supplement detailing the terms of the proposed offering will be submitted to the SEC and will be accessible on the SEC’s website.
About Eyenovia, Inc.
Eyenovia, Inc. is an innovative ophthalmic technology company focused on commercializing Mydcombi for mydriasis, Clobetasol Propionate Ophthalmic Suspension for managing postsurgical inflammation and pain, and is also developing the Optejet device aimed at addressing pediatric progressive myopia and other related conditions.
Contact Information
Eyenovia Contact:
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com
Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
Eyenovia Media Contact:
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com
Frequently Asked Questions
What is the purpose of Eyenovia's public offering?
The public offering aims to finance commercialization activities and clinical studies related to Eyenovia's products.
Who is the placement agent for the offering?
Dawson James Securities, Inc. is the sole placement agent for this offering.
How will Eyenovia utilize the funds from the offering?
The funds will be directed towards various initiatives, including product commercialization, clinical studies, and operational expenses.
Where can I find more information about the offering?
Additional information will be provided in the prospectus supplement that Eyenovia plans to file with the SEC.
What products does Eyenovia focus on?
Eyenovia specializes in ophthalmic products, including Mydcombi and Clobetasol Propionate, and is also developing the Optejet device.
